Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 2,803 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 2,803 shares of the stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $54.00, for a total value of $151,362.00. Following the completion of the transaction, the insider now directly owns 92,231 shares of the company's stock, valued at $4,980,474. This trade represents a 2.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Catriona Yale also recently made the following trade(s):

• On Thursday, May 15th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $39.30, for a total value of $393,000.00.
• On Tuesday, April 15th, Catriona Yale sold 9,073 shares of Akero Therapeutics stock. The shares were sold at an average price of $37.91, for a total value of $343,957.43.
• On Monday, March 17th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.76, for a total value of $447,600.00.

Akero Therapeutics Price Performance

Shares of AKRO traded up $2.06 during midday trading on Friday, reaching $55.62. The stock had a trading volume of 2,224,332 shares, compared to its average volume of 1,009,425. The firm's 50 day moving average price is $43.96 and its 200-day moving average price is $40.36. The company has a market capitalization of $4.43 billion, a P/E ratio of -14.83 and a beta of -0.16. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a 52 week low of $21.02 and a 52 week high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.01) by $1.91. On average, analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Akero Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of AKRO. RTW Investments LP raised its position in shares of Akero Therapeutics by 15.9% during the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock worth $190,840,000 after purchasing an additional 940,388 shares during the period. Deep Track Capital LP raised its position in shares of Akero Therapeutics by 116.0% during the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock worth $41,452,000 after purchasing an additional 800,216 shares during the period. Balyasny Asset Management L.P. acquired a new stake in shares of Akero Therapeutics during the fourth quarter worth $18,059,000. SG Americas Securities LLC raised its position in shares of Akero Therapeutics by 93.3% during the first quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company's stock worth $46,786,000 after purchasing an additional 557,794 shares during the period. Finally, Lord Abbett & CO. LLC acquired a new stake in shares of Akero Therapeutics during the first quarter worth $21,333,000.

Analyst Upgrades and Downgrades

Several analysts have weighed in on AKRO shares. Citigroup cut their target price on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Morgan Stanley reaffirmed an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Bank of America boosted their price objective on Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a research note on Tuesday, May 27th. Finally, HC Wainwright boosted their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Monday, March 3rd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Akero Therapeutics presently has an average rating of "Buy" and an average target price of $82.50.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.